2021
Sars-Cov-2 Vaccination in Patients with Pre-Existing Immune Thrombocytopenia
Lee E, Moreira M, Al-Samkari H, Cuker A, DiRaimo J, Gernsheimer T, Kruse A, Kessler C, Kruse C, Leavitt A, Lee A, Liebman H, Newland A, Ray A, Tarantino M, Thachil J, Kuter D, Cines D, Bussel J. Sars-Cov-2 Vaccination in Patients with Pre-Existing Immune Thrombocytopenia. Blood 2021, 138: 586. PMCID: PMC8701617, DOI: 10.1182/blood-2021-152918.Peer-Reviewed Original ResearchSARS-CoV-2 vaccinesITP exacerbationPre-vaccination baselineBristol-Myers SquibbImmune thrombocytopeniaPlatelet countRescue treatmentDose 2Dose 1Second dosePlatelet decreaseSpeakers bureauSpark TherapeuticsConsultancy feesFirst doseCSL BehringSupport associationsNovo NordiskSARS-CoV-2 vaccinationDiagnosis of ITPAdvisory CommitteeData Safety Monitoring BoardConcurrent autoimmune diseasesMore refractory diseasePrior medical treatment
2019
Daratumumab in the Clinic, a Real-Word Experience at Yale Cancer Center
Browning S, Parker T, Bar N, Seropian S, Lee A, Anderson T, Neparidze N. Daratumumab in the Clinic, a Real-Word Experience at Yale Cancer Center. Blood 2019, 134: 5569. DOI: 10.1182/blood-2019-130134.Peer-Reviewed Original ResearchSmilow Cancer HospitalMultiple myelomaRefractory MMInfusion reactionsSpeakers bureauCancer HospitalReal-word experienceReal-world practice patternsAnti-plasma cell therapyTransplant-eligible patientsYale Cancer CenterInfusion-related reactionsAdverse event profileLeukotriene receptor antagonistsProgression-free survivalRefractory multiple myelomaPatient-reported qualityManagement of patientsOverall response rateJanssen Scientific AffairsClonal plasma cellsExcellent safety profileMulti-center studyDrug combination regimensInfusion reaction rates
2010
Treatment Choice and Outcome In Diffuse Large B Cell Lymphoma (DLBCL) Patients 75 Years and Older
Toomey C, Muzikanksy A, Lee A, Barnes J, Michaelson J, Abramson J, Hochberg E. Treatment Choice and Outcome In Diffuse Large B Cell Lymphoma (DLBCL) Patients 75 Years and Older. Blood 2010, 116: 733. DOI: 10.1182/blood.v116.21.733.733.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaCharlson Comorbidity IndexPatients age 75Patients 75 yearsUse of anthracyclinesComorbidity indexAge 75Elderly patientsOverall survivalPerformance statusPrognostic factorsSpeakers bureauModern chemotherapyAdvanced stageMedian Charlson comorbidity indexOutcome of DLBCLDiagnosis of DLBCLDischarge summariesLarge B-cell lymphomaExtranodal disease sitesHealth-related comorbiditiesECOG performance statusMedian overall survivalPatients 80 yearsAnn Arbor stage
2009
Rituximab Does Not Improve Progression Free (PFS) or Overall Survival (OS) in Patients with Limited Stage Diffuse Large B Cell Lymphoma (DLBCL).
Hochberg E, Birrer N, Toomey C, Barnes J, Lee A, LaCasce A, Abramson J. Rituximab Does Not Improve Progression Free (PFS) or Overall Survival (OS) in Patients with Limited Stage Diffuse Large B Cell Lymphoma (DLBCL). Blood 2009, 114: 3755. DOI: 10.1182/blood.v114.22.3755.3755.Peer-Reviewed Original ResearchLimited stage diffuse large B-cell lymphomaDiffuse large B-cell lymphomaLarge B-cell lymphomaUse of rituximabOverall survivalB-cell lymphomaSpeakers bureauCell lymphomaYounger low-risk patientsPrimary diffuse large B-cell lymphomaDana-Farber Cancer InstituteBenefit of rituximabGood-prognosis populationMultiple retrospective analysesAnthracycline-containing chemotherapyOverall survival benefitPatients 18 yearsLow-risk patientsAdvanced-stage patientsCD20 monoclonal antibodyLarge multicenter trialsTumor registry dataYears of ageMassachusetts General HospitalCurative intent